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10-MINUTE CONSULTATION
Sexual dysfunction in cardiovascular disease
Deborah Morrison GP academic fellow 1, Michael Aitchison consultant urologist 2, Derek T Connelly
consultant cardiologist 3, Frances S Mair professor of primary care research 1
1Academic Unit of General Practice and Primary Care, Institute of Health and WellBeing, University of Glasgow, Glasgow, UK; 2Gartnavel General
Hospital, Glasgow; 3Glasgow Royal Infirmary and Golden Jubilee National Hospital, Glasgow
This is part of a series of occasional articles on common problems in
primary care. The BMJ welcomes contributions from GPs.
A 53 year old man attends for a routine check-up. He underwent
coronary artery bypass grafting after a myocardial infarction
earlier in the year, and seems to be making good progress. He
says he needs to discuss an embarrassing problem. He explains
that he has been having erectile dysfunction, which is making
him miserable and preventing normal marital relations.
What you should cover
• Clarify what the patient means by erectile dysfunction. A
physical cause is more likely with gradual onset, constant
erectile dysfunction with partial or poorly sustained
erections, and no full early morning erections.
• Check duration of the problem—is it entirely new or
worsening of a pre-existing problem?
• Review psychological factors such as performance anxiety,
anxiety about precipitating another coronary event, low
mood, stress, and relationship concerns.
• Ascertain patient’s main concerns or worries.
• Exclude features of hypogonadism such as loss of libido,
loss of body hair, hot flushes, low energy levels,
gynaecomastica, and small testicular size.
• Review current medications, focusing on those that might
cause erectile dysfunction (for example, β blockers,
thiazides, spironolactone, fibrates, cimetidine,
antidepressants, antipsychotics), or drugs that would
contraindicate phosphodiesterase type 5 (PDE5) inhibitors
(such as nitrates and nicorandil). Consider any temporal
association with onset of erectile dysfunction symptoms.
• Review risk factors for sexual dysfunction, such as alcohol
intake, smoking, recreational drugmisuse, and weight gain.
Review risk factors for or symptoms of other medical
conditions (in addition to known cardiovascular disorders)
such as diabetes, prostatic disease, depressive illness,
hypothyroidism, or neurological disorders.1
What you should do
• Physical examination: check blood pressure; examine
genitalia (for small testicular size which may indicate
hypogonadism, fibrosis in the shaft of the penis,
retractability of foreskin); digital rectal examination of the
prostate is indicated in the presence of genitourinary or
protracted secondary ejaculatory symptoms.2
• Stratify patient’s cardiovascular risk (low,
intermediate/indeterminate, or high risk)
• Arrange diagnostic tests—in particular, glucose, cholesterol
(if not measured within previous 12 months), prolactin,
thyroid stimulating hormone, and testosterone levels
between 0800 and 1100. Concentrations of testosterone
may be low owing to illness within the previous 3 months;
if this is the case the test should be repeated after 6-8
weeks.2 Testosterone testing is recommended because
deficiency is reversible and can result in PDE5 inhibitors
being less effective. Normal values vary, so follow local
laboratory guidelines.3
• Checkwhethermedicationsmay be causing or exacerbating
the problem. Consider alternatives that are less likely to
contribute to erectile dysfunction, such as angiotensin
converting enzyme inhibitors, calcium channel blockers
(except verapamil), loop diuretics, and proton pump
inhibitors. Some evidence indicates that angiotensin
receptor blockers may improve sexual function, and could
be the drug of choice for patients with erectile dysfunction
who are newly diagnosed with hypertension.2
• Discuss other potential causes or aggravating factors.
Attention to lifestyle factors and aggressive lipid control
can substantially improve erectile dysfunction with or
without pharmacotherapy. These factors should already be
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being addressed in patients with known cardiovascular
disease, but awareness of this added benefit may aid
compliance.4
• Clarify the patient’s needs, beliefs, concerns, and
expectations.
• Ask whether the patient has discussed erectile dysfunction
with their partner and what the partner’s feelings were.
• Openly discuss the lack of high quality evidence to
underpin treatment decisions and the risks and benefits of
different approaches. Depending on the underlying reasons
for any particular prescriptions, discuss changing to a
different medication or a trial of stopping a medication.
Management options
Manage abnormal blood results, including low testosterone, as
part of follow-up consultations.3
In patients stratified at low cardiovascular risk, consider a PDE5
inhibitor.
• Use of nitrates or nicorandil is an absolute contraindication
to use of PDE5 inhibitors. Review any nitrate
prescription—often patients have not used these drugs since
first diagnosis. If they sporadically use glyceryl trinitrate,
or carry one “just in case”, then it may be reasonable to
prescribe PDE5 inhibitors—ensure that the patient knows
to stop glyceryl trinitrate if chest pain develops after taking
sildenafil or vardenafil (withhold glyceryl trinitrate for 24
hours) or tadalafil (48 hours), or the consequences can be
fatal. Nitrates are usually prescribed for control of angina
symptoms and, unlike calcium channel blockers and β
blockers, they have no prognostic benefit, so replacement
with other anti-anginals could be discussed.2
• PDE5 inhibitors are also contraindicated in patients with
hypotension (avoid if systolic blood pressure below 90mm
Hg), recent stroke, unstable angina, and recent myocardial
infarction (within 6 weeks).4
Arrange follow-up to assess therapeutic outcome in terms of
erectile response, side effects, and patient’s satisfaction with
treatment.
Consider stopping a medication if erectile dysfunction is a
known side effect and if a temporal relation exists, after full
discussion of uncertainties, risks, and benefits.
Consider referral:
• To relationship counselling, sex therapy, or psychology if
relevant. These services are not readily available in some
areas, in which case empirical treatment may be
appropriate.
• To urology or other local service (choice of service varies
considerably) in patients at low cardiovascular risk and
with contraindications to PDE5 inhibitors.
• To urology outpatient clinic for those with history of trauma
to genital area, pelvis, or spine, or if examination shows
an abnormality of penis or testicles.
• To cardiology if cardiovascular risk is
intermediate/indeterminate or high, for further assessment.
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